AACP
AUPH icon

Advantage Alpha Capital Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Advantage Alpha Capital Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,849
Closed -$230K – 11
2025
Q3 		$230K Sell
20,849
-3,230
-13% -$35.3K 0.07% 123
2025
Q2 		$204K Buy
+24,079
New +$193K 0.06% 116

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Advantage Alpha Capital Partners's AUPH Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 20,849 shares — an estimated $230K sold.

Advantage Alpha Capital Partners first reported a position in AUPH in Q2 2025 and held it in 2 quarters. The position peaked at $230K in Q3 2025. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 20,849 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $230K.
  • Advantage Alpha Capital Partners first reported a position in Aurinia Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Advantage Alpha Capital Partners's Aurinia Pharmaceuticals position peaked at $230K in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.